Omnicell (NASDAQ:OMCL) Shares Gap Down - What's Next?

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $35.71, but opened at $33.92. Omnicell shares last traded at $34.07, with a volume of 60,518 shares trading hands.

Analyst Ratings Changes

A number of brokerages have recently weighed in on OMCL. JPMorgan Chase & Co. upped their target price on Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Benchmark reissued a "buy" rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a report on Thursday, March 6th. Bank of America decreased their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Finally, Wells Fargo & Company dropped their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $52.33.

Remove Ads

Omnicell Stock Down 3.2 %

The stock has a 50-day moving average of $40.96 and a 200 day moving average of $43.38. The company has a market capitalization of $1.51 billion, a PE ratio of 119.56, a P/E/G ratio of 7.53 and a beta of 0.85. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Sell-side analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Omnicell by 22.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company's stock valued at $5,306,000 after purchasing an additional 21,847 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of Omnicell by 286.4% in the fourth quarter. Squarepoint Ops LLC now owns 149,717 shares of the company's stock valued at $6,665,000 after buying an additional 110,966 shares during the period. Two Sigma Investments LP lifted its position in shares of Omnicell by 44.2% during the 4th quarter. Two Sigma Investments LP now owns 141,738 shares of the company's stock valued at $6,310,000 after buying an additional 43,471 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Omnicell during the 4th quarter worth $30,637,000. Finally, Point72 Hong Kong Ltd purchased a new stake in Omnicell in the 4th quarter worth about $101,000. 97.70% of the stock is owned by institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.